Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cynaroside to preparation of medicine for treating or preventing hand-foot-and-mouth diseases

A technology for hand, foot and mouth disease and luteolin, applied in the field of medicine, can solve the problem that no literature reports luteolin against hand, foot and mouth disease, etc., and achieve the effect of various administration methods.

Inactive Publication Date: 2016-09-07
JIANGSU KANION PHARMA CO LTD
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report on the application of luteolin in anti-hand, foot and mouth disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cynaroside to preparation of medicine for treating or preventing hand-foot-and-mouth diseases
  • Application of cynaroside to preparation of medicine for treating or preventing hand-foot-and-mouth diseases
  • Application of cynaroside to preparation of medicine for treating or preventing hand-foot-and-mouth diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Vero cytotoxicity of luteolin

[0025] 1. Materials and methods

[0026] 1.1 Cells and culture methods

[0027] African green monkey kidney cells (Vero cells) were used as the cell model (provided by the Institute of Microbial Epidemiology, Academy of Military Medical Sciences, the same below), and cultured in M199 containing 10% fetal bovine serum (Gibco company, batch number: 1376154, the same below). Base (Hyclone company, batch number: NZC1116, the same below), placed at 37 ° C, 5% CO 2 Cultivate in an incubator, and subculture when the cells grow to 90% density, and the ratio of cell subculture is 1 / 3-1 / 4.

[0028] 1.2 Reagents

[0029] MTS Cell Proliferation Quantitative Detection Kit (purchased from Promega, batch number: 00000657694, the same below); Luteolin (purchased from Shanghai Eternal Biotechnology Co., Ltd., batch number: 20100423, the same below).

[0030] 1.3 Instruments

[0031] Microplate reader (purchased from Molecular Devices, model...

Embodiment 2

[0041] Example 2 Protection of luteolin on Vero cells infected by EV71 and CoxA16 viruses and inhibition of virus replication

[0042] 1. Materials and methods

[0043] 1.1 Cells and culture methods

[0044] African green monkey kidney cells (Vero cells) were used as the cell model, and M199 medium containing 10% fetal bovine serum was used at 37°C and 5% CO 2 Cultivate in an incubator, and subculture when the cells grow to 90% density, and the ratio of cell subculture is 1 / 3-1 / 4.

[0045] 1.2 Virus strains

[0046] EV71 virus BJ09 / 07 strain, GenBank accession number JQ319054.1; CoxA16 virus TS10 / 08 strain, GenBank accession number JX068829, all provided by the Institute of Microbial Epidemiology, Academy of Military Medical Sciences, the same below. Determine the half cytopathic dose (TCID) of EV71 virus before use 50 ) is 10 7 / mL, CoxA16TCID 50 for 10 7.5 / mL.

[0047] 1.3 Reagents

[0048] MTS cell proliferation quantitative detection kit (purchased from Promega, ...

Embodiment 3

[0066] Example 3 Broad-spectrum study of luteolin against hand-foot-mouth virus

[0067] 1. Materials and methods

[0068] 1.1 Cells and culture methods

[0069] African green monkey kidney cells (Vero cells) were used as the cell model, and the cells with the number of passages between 130 and 145 were used in the experiment. Cells were cultured in M199 medium containing 10% fetal bovine serum at 37°C, 5% CO 2 Cultivate in an incubator, and subculture when the cells grow to 90% density, and the subculture ratio is 1 / 3-1 / 4.

[0070] 1.2 Virus strains

[0071] Coxsackieviruses A groups 4, 5, 7, 9 and 10 (CoxA4, CoxA5, CoxA7, CoxA9 and CoxA10), Coxsackieviruses B groups 2 and 5 (CoxB2 and CoxB5) and echoviruses (ECHO) . Measure the TCID of each virus before use 50 10 respectively 6 、10 7 、10 7.5 、10 5 、10 8 、10 6.5 、10 7.5 and 10 6 / mL, the above viruses were provided by the Wuhan Institute of Virology, Chinese Academy of Sciences.

[0072] 1.3 Reagents

[0073] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of cynaroside to preparation of a medicine for treating or preventing hand-foot-and-mouth diseases. The hand-foot-and-mouth diseases are caused by an enterovirus type 71, a type 16, type 4, type 5, type 7, type 9 and type 10 of a coxsackie virus group A, a type 2 and type 5 of a coxsackie virus group B or an echovirus. The medicine takes the cynaroside as an active component and is mixed with a pharmaceutically acceptable auxiliary material to prepare any one clinically acceptable dosage form. The application disclosed by the invention provides a new way for treating the hand-foot-and-mouth diseases; the cynaroside can be developed as a new medicine for preventing the hand-foot-and-mouth diseases; the toxic and side effects are small; the lesion of infected cells is inhibited, a dose-dependent effect is realized and the medicine is a broad-spectrum antiviral medicine; virus replication is inhibited, the virus load in host cells is reduced and viruses are promoted to become negative; the case fatality rate is reduced or eliminated and the survival time of illness cases is prolonged; the content of cell factors is reduced and inflammations caused by virus infection is alleviated; a plurality of administration manners are provided and the medicine can be administrated by injection and can also be orally taken.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of luteolin in the preparation of medicines for treating or preventing hand, foot and mouth disease. technical background [0002] Hand, foot and mouth disease is a childhood infectious disease caused by a virus, and it is a legal Class C infectious disease in my country. The disease mainly affects infants and young children aged 0-6, and children aged 2-3 are the most common infection. In the early stage of hand, foot and mouth disease, herpes or ulcers are caused on the extremities and mouth of the children, and most of the children are within 1-2 weeks. get well. However, a small number of cases progress rapidly, and meningitis, aseptic encephalitis, brainstem encephalitis, encephalomyelitis, pulmonary edema, and circulatory disorders may occur within 1-5 days of onset. Death and sequelae may be left in surviving cases. [0003] According to the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P31/14
CPCA61K31/7048
Inventor 萧伟曹泽彧丁玥曹亮王振中
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com